Literature DB >> 32994364

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.

Ellen Shrock1,2, Eric Fujimura1,2,3, Tomasz Kula1,2, Richard T Timms1,2, I-Hsiu Lee4, Yumei Leng1,2, Matthew L Robinson5, Brandon M Sie1,2, Mamie Z Li1,2, Yuezhou Chen6,7, Jennifer Logue8, Adam Zuiani6,7, Denise McCulloch8, Felipe J N Lelis6,7, Stephanie Henson9, Daniel R Monaco9, Meghan Travers6,7, Shaghayegh Habibi6,7, William A Clarke10, Patrizio Caturegli11, Oliver Laeyendecker5,12, Alicja Piechocka-Trocha7,13, Jonathan Z Li7,14, Ashok Khatri15, Helen Y Chu8, Alexandra-Chloé Villani16, Kyle Kays17, Marcia B Goldberg18, Nir Hacohen19, Michael R Filbin17, Xu G Yu7,14,20,21, Bruce D Walker7,13,22, Duane R Wesemann6,7, H Benjamin Larman9, James A Lederer23, Stephen J Elledge24,2,7.   

Abstract

Understanding humoral responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for improving diagnostics, therapeutics, and vaccines. Deep serological profiling of 232 coronavirus disease 2019 (COVID-19) patients and 190 pre-COVID-19 era controls using VirScan revealed more than 800 epitopes in the SARS-CoV-2 proteome, including 10 epitopes likely recognized by neutralizing antibodies. Preexisting antibodies in controls recognized SARS-CoV-2 ORF1, whereas only COVID-19 patient antibodies primarily recognized spike protein and nucleoprotein. A machine learning model trained on VirScan data predicted SARS-CoV-2 exposure history with 99% sensitivity and 98% specificity; a rapid Luminex-based diagnostic was developed from the most discriminatory SARS-CoV-2 peptides. Individuals with more severe COVID-19 exhibited stronger and broader SARS-CoV-2 responses, weaker antibody responses to prior infections, and higher incidence of cytomegalovirus and herpes simplex virus 1, possibly influenced by demographic covariates. Among hospitalized patients, males produce stronger SARS-CoV-2 antibody responses than females.
Copyright © 2020, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32994364      PMCID: PMC7857405          DOI: 10.1126/science.abd4250

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   63.714


  36 in total

1.  The neighbor-joining method: a new method for reconstructing phylogenetic trees.

Authors:  N Saitou; M Nei
Journal:  Mol Biol Evol       Date:  1987-07       Impact factor: 16.240

2.  Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004.

Authors:  Sheri Lewis Bate; Sheila C Dollard; Michael J Cannon
Journal:  Clin Infect Dis       Date:  2010-06-01       Impact factor: 9.079

Review 3.  Immunosenescence, suppression and tumour progression.

Authors:  G Pawelec; S Koch; H Griesemann; A Rehbein; K Hähnel; C Gouttefangeas
Journal:  Cancer Immunol Immunother       Date:  2005-12-06       Impact factor: 6.968

4.  Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum.

Authors:  Geoffrey J Gorse; Gira B Patel; Joseph N Vitale; Theresa Z O'Connor
Journal:  Clin Vaccine Immunol       Date:  2010-10-13

Review 5.  Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).

Authors:  Dae-Gyun Ahn; Hye-Jin Shin; Mi-Hwa Kim; Sunhee Lee; Hae-Soo Kim; Jinjong Myoung; Bum-Tae Kim; Seong-Jun Kim
Journal:  J Microbiol Biotechnol       Date:  2020-03-28       Impact factor: 2.351

6.  BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes.

Authors:  Martin Closter Jespersen; Bjoern Peters; Morten Nielsen; Paolo Marcatili
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

Review 7.  Origin and evolution of pathogenic coronaviruses.

Authors:  Jie Cui; Fang Li; Zheng-Li Shi
Journal:  Nat Rev Microbiol       Date:  2019-03       Impact factor: 60.633

Review 8.  COVID-19 pathophysiology: A review.

Authors:  Koichi Yuki; Miho Fujiogi; Sophia Koutsogiannaki
Journal:  Clin Immunol       Date:  2020-04-20       Impact factor: 3.969

9.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.

Authors:  Alexandra C Walls; Young-Jun Park; M Alejandra Tortorici; Abigail Wall; Andrew T McGuire; David Veesler
Journal:  Cell       Date:  2020-03-09       Impact factor: 41.582

10.  Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins.

Authors:  Sheng-Fan Wang; Sung-Pin Tseng; Chia-Hung Yen; Jyh-Yuan Yang; Ching-Han Tsao; Chun-Wei Shen; Kuan-Hsuan Chen; Fu-Tong Liu; Wu-Tse Liu; Yi-Ming Arthur Chen; Jason C Huang
Journal:  Biochem Biophys Res Commun       Date:  2014-07-26       Impact factor: 3.575

View more
  190 in total

1.  Nature's second pandemic progress report.

Authors: 
Journal:  Nature       Date:  2020-10       Impact factor: 49.962

Review 2.  Nowcasting epidemics of novel pathogens: lessons from COVID-19.

Authors:  Joseph T Wu; Kathy Leung; Tommy T Y Lam; Michael Y Ni; Carlos K H Wong; J S Malik Peiris; Gabriel M Leung
Journal:  Nat Med       Date:  2021-03-15       Impact factor: 53.440

3.  SARS-CoV-2 variants: Subversion of antibody response and predicted impact on T cell recognition.

Authors:  Daniel M Altmann; Catherine J Reynolds; Rosemary J Boyton
Journal:  Cell Rep Med       Date:  2021-05-18

4.  Longitudinal Analysis of COVID-19 Patients Shows Age-Associated T Cell Changes Independent of Ongoing Ill-Health.

Authors:  Liam Townsend; Adam H Dyer; Aifric Naughton; Rachel Kiersey; Dean Holden; Mary Gardiner; Joanne Dowds; Kate O'Brien; Ciaran Bannan; Parthiban Nadarajan; Jean Dunne; Ignacio Martin-Loeches; Padraic G Fallon; Colm Bergin; Cliona O'Farrelly; Cliona Ni Cheallaigh; Nollaig M Bourke; Niall Conlon
Journal:  Front Immunol       Date:  2021-05-07       Impact factor: 7.561

Review 5.  Review of Current COVID-19 Diagnostics and Opportunities for Further Development.

Authors:  Yan Mardian; Herman Kosasih; Muhammad Karyana; Aaron Neal; Chuen-Yen Lau
Journal:  Front Med (Lausanne)       Date:  2021-05-07

6.  Breadth and function of antibody response to acute SARS-CoV-2 infection in humans.

Authors:  Kuan-Ying A Huang; Tiong Kit Tan; Ting-Hua Chen; Chung-Guei Huang; Ruth Harvey; Saira Hussain; Cheng-Pin Chen; Adam Harding; Javier Gilbert-Jaramillo; Xu Liu; Michael Knight; Lisa Schimanski; Shin-Ru Shih; Yi-Chun Lin; Chien-Yu Cheng; Shu-Hsing Cheng; Yhu-Chering Huang; Tzou-Yien Lin; Jia-Tsrong Jan; Che Ma; William James; Rodney S Daniels; John W McCauley; Pramila Rijal; Alain R Townsend
Journal:  PLoS Pathog       Date:  2021-02-26       Impact factor: 6.823

Review 7.  Immune profiling of COVID-19: preliminary findings and implications for the pandemic.

Authors:  Holden T Maecker
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

8.  Immune age and biological age as determinants of vaccine responsiveness among elderly populations: the Human Immunomics Initiative research program.

Authors:  Jaap Goudsmit; Anita Huiberdina Johanna van den Biggelaar; Wouter Koudstaal; Albert Hofman; Wayne Chester Koff; Theodore Schenkelberg; Galit Alter; Michael Joseph Mina; Julia Wei Wu
Journal:  Eur J Epidemiol       Date:  2021-06-12       Impact factor: 8.082

Review 9.  SARS-CoV-2 variants, spike mutations and immune escape.

Authors:  William T Harvey; Alessandro M Carabelli; Ben Jackson; Ravindra K Gupta; Emma C Thomson; Ewan M Harrison; Catherine Ludden; Richard Reeve; Andrew Rambaut; Sharon J Peacock; David L Robertson
Journal:  Nat Rev Microbiol       Date:  2021-06-01       Impact factor: 78.297

Review 10.  Natural killer cells in antiviral immunity.

Authors:  Niklas K Björkström; Benedikt Strunz; Hans-Gustaf Ljunggren
Journal:  Nat Rev Immunol       Date:  2021-06-11       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.